City Therapeutics and Strive set pricing for their respective IPOs

The initial public offerings for two companies were structured after establishing their respective subscription costs on October 16, 2026, as reported by Investing.com. The operations mark the arrival of new equity issues to the markets through two placement structures differentiated by asset class and capital volume.

City Therapeutics determined an exit price of 18 dollars per share for its initial public offering (IPO), a financial operation through which a company places securities for the first time among institutional and retail investors. At this price level, the company raised 200 million dollars in capital.

Strive, meanwhile, finalized the price of its public offering at 90 dollars per share, according to data published by the same financial platform. The operation was structured as preferred stock, an asset class that grants priority in dividend payments over common shares in exchange for limiting or excluding corporate voting rights, and corresponded to an expanded placement modality.

Known terms of the two stock market operations

Data published by Investing.com detail that City Therapeutics reached a total of 200 million dollars after setting the individual price at 18 dollars. This figure represents the gross amount obtained by the firm from the number of shares put into circulation in the primary market.

In the case of Strive, the placement was executed using an expanded format compared to the original issuance plan. The final pricing value was set at 90 dollars for each preferred share, which determines the initial subscription cost for the entities and portfolios participating in the order book.

Structural differences between both issuances

The main distinction between both operations lies in the financial instrument used for fundraising. City Therapeutics opted for an IPO of standard shares, whose unit value of 18 dollars is aimed at the general shareholder base with proportional participation in the capital.

Strive turned to the preferred stock segment with a unit valuation five times higher than that of City Therapeutics. This type of instrument usually seeks holders who prioritize predetermined periodic flows and capital protection against the direct volatility of ordinary stock prices.

Information pending in official records

Sources have not made public additional breakdowns regarding the exact volume of preferred shares assigned by Strive or the total amount raised after the expansion of its issuance. Nor were the specific exchanges where secondary trading will begin for either company specified.

It remains to be seen which investment banks led the book-building process for both operations, as well as the timelines set for the start of effective trading under their corresponding ticker symbols.

The key point to monitor will be the performance of both securities during their secondary market debut and the volume traded during their first transactions.